

## DEPOSITARY RECEIPTS

### NEW DR ANNOUNCEMENT

March 10, 2015

### Summit Therapeutics plc

Summit Therapeutics is an international biopharmaceutical company based in the United Kingdom. The Company is focused on discovering and developing advanced medicines to treat areas of unmet medical need. The Company's operating focus is on two therapy areas, namely, the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and the infectious disease Clostridium difficile Infection (CDI). The Company has established partnerships with a range of philanthropic, not-for-profit organizations and government entities to support the development of its DMD and CDI programs. These entities include the Wellcome Trust, Innovate U.K. and a range of DMD patient advocacy groups.

|                                      |                             |
|--------------------------------------|-----------------------------|
| <b>Effective Date:</b>               | March 10, 2015              |
| <b>Country of Incorporation:</b>     | United Kingdom              |
| <b>Exchange:</b>                     | NASDAQ Stock Market         |
| <b>Type of ADR Program:</b>          | Sponsored - Level III       |
| <b>Ticker Symbol:</b>                | SMMT                        |
| <b>CUSIP Number:</b>                 | 86627R102                   |
| <b>Ratio (DR:ORD):</b>               | 1 : 5                       |
| <b>Underlying Share Description:</b> | Ordinary                    |
| <b>Industry Classification:</b>      | Pharma. & Biotech.          |
| <b>Custodian(s) :</b>                | The Bank of New York Mellon |

To learn more about ADRs and issuer programs, please call our marketing desks:

#### New York

Ravi Davis  
Adrdesk@bnymellon.com  
Tel: 212 815 2267

#### Hong Kong

Herston Powers  
Vice President  
herston.powers@bnymellon.com  
Tel: 852 2840 9868

#### London

Damon Rowan  
Vice President  
damon.rowan@bnymellon.com  
Tel: 442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.